Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1 - 4

This study has been completed.

First Received: September 20, 1999 Last Updated: November 3, 2005 History of Changes

Sponsors and Collaborators:	National Institute on Drug Abuse (NIDA) University of Colorado at Denver and Health Sciences Center
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000329

Purpose

The purpose of this study is to assess the abuse liability and examine the reinforcing effects of intravenous buprenorphine and buprenorphine/naloxone combinations in buprenorphine-naloxone maintained volunteers

Condition	Intervention	Phase
Heroin Dependence Opioid-Related Disorders	Drug: Opioid-Related Disorders	Phase II

Study Type:	Interventional
Study Design:	Treatment, Double-Blind, Placebo Control
Official Title:	Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1

Resource links provided by NLM:

MedlinePlus related topics: Heroin

Drug Information available for: Buprenorphine Buprenorphine hydrochloride Naloxone

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Subjective dose estimate
Observed withdrawal rating
Opioid agonist rating
Opioid antagonist rating
Pupil diameter
Analog rating scale for drug effects
Drug effect characteristics
Drug/Money Preferences

Estimated Enrollment:	0
Study Start Date:	April 1999

Detailed Description:

Ongoing study - results not available at this time

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Individuals must be at least 18 yrs of age, currently opioid dependent and meet FDA critera for narcotic maintenance treatment. Co-morbid substance abuse or dependence disorders may also be present. Individuals must be healthy despite drug dependency and have a history of IV opioid use.

Exclusion Criteria:

Individuals with evidence of anti active DSM-IV Axis I psychiatric disorder (e.g. psychosis, manic-depressive illness, organic psychiatric disorders), significant medical illness (e.g. liver or cardiovascular disease) or pregnant female subjects are excluded from study participation.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000329

Locations

United States, Colorado
University of Colorado Health Sciences Center
Denver, Colorado, United States, 80206

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

University of Colorado at Denver and Health Sciences Center

Investigators

Principal Investigator:

Leslie Amass, Ph.D.

University of Colorado at Denver and Health Sciences Center

More Information

No publications provided

Study ID Numbers:	NIDA-11160-4, R01-11160-4
Study First Received:	September 20, 1999
Last Updated:	November 3, 2005
ClinicalTrials.gov Identifier:	NCT00000329 History of Changes
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Heroin Dependence
Narcotic Antagonists
Disorders of Environmental Origin
Central Nervous System Depressants
Narcotics
Opioid-Related Disorders
Naloxone

Buprenorphine
Mental Disorders
Substance-Related Disorders
Analgesics
Peripheral Nervous System Agents
Analgesics, Opioid

Additional relevant MeSH terms:

Heroin Dependence
Narcotic Antagonists
Physiological Effects of Drugs
Central Nervous System Depressants
Disorders of Environmental Origin
Narcotics
Opioid-Related Disorders
Pharmacologic Actions
Buprenorphine

Mental Disorders
Sensory System Agents
Therapeutic Uses
Substance-Related Disorders
Analgesics
Peripheral Nervous System Agents
Central Nervous System Agents
Analgesics, Opioid

ClinicalTrials.gov processed this record on July 02, 2009